Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio
FDA Approves Genentech's Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema , a Serious Cause of Vision Loss
FDA Approves Genentech's Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
Genentech and Breastcancer.org Say It's "About Damn Time" We Talk About What Happens When Initial Breast Cancer Treatment Ends
Genentech Presents New Data at EURETINA, Highlighting Vabysmo's Real-World Effectiveness and Safety Across Major Retinal Conditions
Genentech's Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
Genentech's Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
Positive Interim Data Shows Genentech's Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy
Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
Angkor Resources Presents Its Proposed 2027 Work Program For Block Viii To The Cambodian Government At The Joint Review Committee
Blue Jay Gold Announces Materials Purchase Agreement With Ocean Partners for Remediation Material at Steller
SAGA Metals Completes Diamond Drill Program at the Wolverine Rare Earth Project - All 22 Holes Totalling 3,241 Metres Intersect Prospective REE-Bearing Alteration
